OUTLOOK THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.58 USD | -1.94% |
|
-11.86% | -3.81% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 204K | Sales 2025 * | 11.85M | Capitalization | 177M |
|---|---|---|---|---|---|
| Net income 2024 * | -72M | Net income 2025 * | -62M | EV / Sales 2024 * | 867 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 14.9 x |
| P/E ratio 2024 * |
-2.27
x | P/E ratio 2025 * |
-3.26
x | Employees | 24 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.53% |
More Fundamentals
* Assessed data
More news
Latest transcript on Outlook Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -1.94% | ||
| 1 week | -11.86% | ||
| Current month | -15.02% | ||
| 1 month | -15.68% | ||
| 3 months | -8.48% | ||
| 6 months | -5.25% | ||
| Current year | -3.81% |
1 week
7.53
8.91
1 month
7.539.29
Current year
5.0412.85
1 year
4.0040.60
3 years
4.0065.40
5 years
4.0085.20
10 years
4.00878.40
| Managers | Title | Age | Since |
|---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 18-04-12 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 15-12-10 |
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +9.18% | - | |
| 0.00% | 0 M€ | +4.20% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 7.58 | -1.94% | 392,664 |
| 24-05-09 | 7.73 | -3.37% | 223,914 |
| 24-05-08 | 8 | -2.56% | 455,100 |
| 24-05-07 | 8.21 | -3.41% | 200,305 |
| 24-05-06 | 8.5 | -1.16% | 241,264 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
Calendar
2024-05-15
- Q2 2024 Earnings Release
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.58
USD
Average target price
39.86
USD
Spread / Average Target
+425.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.81% | 177M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- OTLK Stock
